Form 4: Redmile Group Acquires Stock Options in IGM Biosciences Through Director Deputization

Redmile Group, through its managing director Mike Lee's board service at IGM Biosciences, acquired stock options, with Jeremy Green and Redmile disclaiming beneficial ownership except for their pecuniary interest.

Summary

• Redmile Group, LLC, through its managing director Mike Lee, acquired 29,400 stock options in IGM Biosciences on March 12, 2024.
• The options have an exercise price of $9.95 and expire on March 12, 2034.
• The options vest monthly after IGM Biosciences' first annual stockholder meeting following the grant date, but will fully vest by the earlier of the 12-month anniversary of the Annual Meeting or the date of the Issuer's next annual stockholder meeting.
• Jeremy Green, as principal of Redmile, may also be deemed to beneficially own the stock option.
• Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction related to stock options. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The acquisition of stock options indicates Redmile Group's continued investment in IGM Biosciences.
• The vesting schedule incentivizes continued service by Mike Lee on the Board of Directors.

Future Outlook

The document does not contain specific forward-looking statements regarding IGM Biosciences' future performance.

Industry Context

This filing reflects routine transactions by significant shareholders and insiders, which are common in the biotechnology industry. Such transactions can be indicative of the investor's confidence in the company's prospects, but should be viewed in the context of the investor's overall portfolio and investment strategy.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotech industry to align their interests with those of shareholders.
• Vesting schedules are typically structured to incentivize long-term commitment and performance.
• Similar transactions can be observed in filings by other biotech companies such as Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the interests of a board member with the company's performance.
• Employees may view this as a positive sign of continued investment in the company.

Key Dates